Literature DB >> 25760537

Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4.

Hanaka Mimura1, Kaoru Kobayashi2, Linxiaoqing Xu1, Mari Hashimoto1, Yoko Ejiri3, Masaya Hosoda3, Kan Chiba1.   

Abstract

The expression of hepatic cytochrome P450 (CYP) enzymes is altered under pathological conditions with increased levels of cytokines. In this study, we analyzed the effects of cytokines (interleukin [IL]-1β, IL-6 and tumor necrosis factor α) on the expression of CYP3A4 using newly introduced three-dimensionally cultured human hepatocarcinoma FLC-4 cells. The mRNA level of CYP3A4 was significantly decreased by IL-1β, IL-6 and tumor necrosis factor-α. Formation of α-hydroxytriazolam catalyzed by CYP3A was decreased by IL-1β and IL-6. Pre-treatment with IL-6 enhanced the cytotoxic effects of gefitinib and paclitaxel. In addition, tocilizumab and IL-1 receptor antagonist restored the decreased expression of CYP3A4 mRNA by IL-6 and IL-1β, respectively. These results obtained by using three-dimensionally cultured FLC-4 cells are consistent with results obtained by using primary human hepatocytes and results of clinical studies. Therefore, three-dimensionally cultured FLC-4 cell system may be a promising cellular tool to assess the effects of cytokines on CYP3A4 expression.
Copyright © 2014 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CYP3A4; Cytokine; Expression; IL-1ra; Tocilizumab

Mesh:

Substances:

Year:  2014        PMID: 25760537     DOI: 10.1016/j.dmpk.2014.09.004

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  10 in total

1.  Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein.

Authors:  B Clarivet; P Robin; Y M Pers; R Ferreira; J Lebrun; C Jorgensen; D Hillaire-Buys; V Brés; J L Faillie
Journal:  Eur J Clin Pharmacol       Date:  2016-07-26       Impact factor: 2.953

Review 2.  Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.

Authors:  Flavia Storelli; Caroline Samer; Jean-Luc Reny; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

3.  Increased Tacrolimus Exposure in Kidney Transplant Recipients With COVID-19: Inflammation-Driven Downregulation of Metabolism as a Potential Mechanism.

Authors:  Sylvia D Klomp; Soufian Meziyerh; Maurits F J M Vissers; Dirk J A R Moes; Eline J Arends; Y K Onno Teng; Jesse J Swen; Aiko P J de Vries
Journal:  Transpl Int       Date:  2022-05-16       Impact factor: 3.842

4.  Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients.

Authors:  Hikaru Sato; Takafumi Naito; Takuya Ishida; Junichi Kawakami
Journal:  Eur J Clin Pharmacol       Date:  2016-08-26       Impact factor: 2.953

5.  Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab.

Authors:  John D Davis; Ashish Bansal; David Hassman; Bolanle Akinlade; Meng Li; Zhaoyang Li; Brian Swanson; Jennifer D Hamilton; A Thomas DiCioccio
Journal:  Clin Pharmacol Ther       Date:  2018-04-02       Impact factor: 6.875

Review 6.  Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients.

Authors:  Subrata Deb; Scott Arrighi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-03       Impact factor: 2.441

Review 7.  Disease-drug and drug-drug interaction in COVID-19: Risk and assessment.

Authors:  Devendra Kumar; Neerja Trivedi
Journal:  Biomed Pharmacother       Date:  2021-04-27       Impact factor: 7.419

8.  Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms.

Authors:  Mahmoud A El-Ghiaty; Sherif M Shoieb; Ayman O S El-Kadi
Journal:  Med Hypotheses       Date:  2020-06-26       Impact factor: 1.538

9.  CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients.

Authors:  Máté Déri; Zsófia Szakál-Tóth; Ferenc Fekete; Katalin Mangó; Evelyn Incze; Annamária Minus; Béla Merkely; Balázs Sax; Katalin Monostory
Journal:  Sci Rep       Date:  2021-11-01       Impact factor: 4.379

10.  Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism.

Authors:  Jakob Mühlbacher; Christian Schörgenhofer; Konstantin Doberer; Michael Dürr; Klemens Budde; Farsad Eskandary; Katharina A Mayer; Sabine Schranz; Sarah Ely; Birgit Reiter; Edward Chong; Scott H Adler; Bernd Jilma; Georg A Böhmig
Journal:  Transpl Int       Date:  2021-07-08       Impact factor: 3.782

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.